SpyBiotech Revenue and Competitors

Oxford,

Location

#5249

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • SpyBiotech's estimated annual revenue is currently $4M per year.(i)
  • SpyBiotech's estimated revenue per employee is $155,000

Employee Data

  • SpyBiotech has 26 Employees.(i)
  • SpyBiotech grew their employee count by 30% last year.

SpyBiotech's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Principal ScientistReveal Email/Phone
3
ScientistReveal Email/Phone
4
Senior Scientist ImmunologyReveal Email/Phone
5
Financial ControllerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is SpyBiotech?

SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimises delivery risk and enhances immunogenicity and efficacy. SpyBiotech has the exclusive rights from the University of Oxford to apply, commercialise and sub-license the SpyTag/SpyCatcher technology in vaccine development. The company's current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for 2021. SpyBiotech is supported by high quality investors including Oxford Sciences Innovation (OSI), the capital investor for the University of Oxford, and GV (formally Google Ventures). The company has raised £15 million of funding to date.

keywords:N/A

N/A

Total Funding

26

Number of Employees

$4M

Revenue (est)

30%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.8M268%N/A
#2
$2.6M26-10%N/A
#3
N/A264%N/A
#4
$4.6M26-4%N/A
#5
$3.4M27N/AN/A